Clinical Trial Update: Safety Study of Infusion of SGT-53 to Treat Solid Tumors [Phase 1]

View source ↗

Summary

Completion of a Phase 1 safety study evaluating infusion of SGT-53 for treating solid tumors, sponsored by SynerGene Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• SGT-53

Snippet

Sponsor: SynerGene Therapeutics, Inc. | Conditions: Neoplasm | Phase 1 | Status: COMPLETED